TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00955968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Description: A combination of three or more HIV medications belonging to two or more drug classes.~The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC). Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV), didanosine (ddI), atazanavir (ATV), raltegravir (RAL), and ritonavir (RTV). While LPV/RTV plus TDF/FTC was the preferred study-supplied regimen, the study clinicians in conjunction with participants would determine the optimal drug combination for each participant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Highly active antiretroviral therapy (HAART)
Description: A combination of three or more HIV medications belonging to two or more drug classes.~The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC). Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV), didanosine (ddI), atazanavir (ATV), raltegravir (RAL), and ritonavir (RTV). While LPV/RTV plus TDF/FTC was the preferred study-supplied regimen, the study clinicians in conjunction with participants would determine the optimal drug combination for each participant.
Study: NCT01764724

Intervention type: BEHAVIORAL
Intervention: Mock package questionnaire
Description: Within a online questionnaire we exposed participants randomly to 4 mock packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
Study: NCT01348113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Alcohol intervention
Description: Brief intervention consists typically in a brief assessment, giving patients personal feedback, dealing with resistance and ambivalence, establishing a goal of reduced alcohol use, and giving a workbook; reinforcement visits or calls are included.
Study: NCT00401544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: Darbepoetin alfa administered by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: Darbepoetin alfa administered by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: Darbepoetin alfa administered by subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: Darbepoetin alfa administered by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV iron dextran
Description: Administered by intravenous (IV) injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV iron dextran
Description: Administered by intravenous (IV) injection.
Study: NCT02300350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A digoxin
Description: 0.5 mg digoxin administered on Day 1 and Day 20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B LX4211
Description: 400 mg LX4211 administered daily on Day 14 through Day 25

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C Digoxin + 400 mg LX4211 administered concomitantly
Description: 0.5 mg Digoxin + 400 mg LX4211 administered concomitantly on Day 20
Study: NCT04397471

Intervention type: PROCEDURE
Intervention: Bone Marrow Harvest
Description: Healthy volunteer bone marrow harvest
Study: NCT02440321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-child interactive program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: written materials
Study: NCT01591551

Intervention type: DRUG
Group type: OTHER
Intervention: Natalizumab (Tysabri)
Description: 300 mg IV every 4 weeks
Study: NCT04616105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN6490
Description: Single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN6490
Description: Single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN6490
Description: Single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN6490
Description: Single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of REGN6490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of REGN6490
Study: NCT02680184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: CMP-001 will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: CMP-001 will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: CMP-001 will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as per the schedule specified in the respective arms.
Study: NCT04603794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Povidone Iodine
Description: Commercially Available Mouth Rinses and Over the Counter Standard Formulations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.12% Chlorhexidine Gluconate Mouth Rinse
Description: Commercially Available Mouth Rinses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Hydrogen Peroxide
Description: Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
Study: NCT04164823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical taping
Description: For the medical taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic self-medication (OTC)
Description: Participants will note the usual analgesic self-medication used to relief pain (ibuprofen, acetaminophen...).
Study: NCT03404258

Intervention type: OTHER
Intervention: Research Blood Sampling
Description: Blood samples will be collected at specified time points and research assays will be performed.

Intervention type: OTHER
Intervention: Research Blood Sampling
Description: Blood samples will be collected at specified time points and research assays will be performed.
Study: NCT02611921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator
Study: NCT05581992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Capsule
Study: NCT02035098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the Pac-IFicO programme
Description: The Pac-IFicO programme is a complex interventions with multiple components. It includes focus group with ward professionals for identifying possible local obstacles to optimal pain control, informative material for the patients, an educational programs performed through guides from the wards, and an organisational intervention to the ward.
Study: NCT00733564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Paracervical injection of 2% Lidocaine to block associated nociception input

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 3mg/kg will be injected intravenously; 1 mg/kg will be added additionally for incomplete anesthesia
Study: NCT02153229

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Pleurectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Pleurectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photofrin 2.0 mg/kg
Description: If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
Study: NCT04568525

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Passive Microwave Radiometry
Description: The MWR2020 (ormer RTM-01-RES) device is a unique commercially available CE marked device. It is registered in UK MHRA MDN 40802 as Microwave thermography system for clinical studies. The device is already registered in Kyrgyzstan for breast cancer diagnostics. During the 1980-90s there were several works on identification of excess of microwave emission due to fluid in lungs (on phantoms) which could be indication of inflammatory, process, cancer and other lung disorders.Later results were confirmed by clinical studies for lung cancer
Study: NCT00733564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane 8% for anesthesia induction, 2-3% as the maintenance
Study: NCT04568525

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Passive Microwave Radiometry
Description: The MWR2020 (ormer RTM-01-RES) device is a unique commercially available CE marked device. It is registered in UK MHRA MDN 40802 as Microwave thermography system for clinical studies. The device is already registered in Kyrgyzstan for breast cancer diagnostics. During the 1980-90s there were several works on identification of excess of microwave emission due to fluid in lungs (on phantoms) which could be indication of inflammatory, process, cancer and other lung disorders.Later results were confirmed by clinical studies for lung cancer

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Passive Microwave Radiometry
Description: The MWR2020 (ormer RTM-01-RES) device is a unique commercially available CE marked device. It is registered in UK MHRA MDN 40802 as Microwave thermography system for clinical studies. The device is already registered in Kyrgyzstan for breast cancer diagnostics. During the 1980-90s there were several works on identification of excess of microwave emission due to fluid in lungs (on phantoms) which could be indication of inflammatory, process, cancer and other lung disorders.Later results were confirmed by clinical studies for lung cancer
Study: NCT00038623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yttrium-ibritumomab (Zevalin)
Description: After Rituximab infusion, 111\^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 250 mg/m\^2 in the vein over 6 to 8 hours on Day 1.
Study: NCT06402591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: cefazolin extended prophylaxis 5 days (15 doses)
Study: NCT01291576

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal/colorectal segmental resection
Description: Resection of the rectum +/- sigmoid colon involved by the deep infiltrating endometriosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal nodule excision
Description: Either full thickness excision or rectal shaving
Study: NCT05656703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS guidance of anesthesia
Description: Anesthesia is to be directed to a specific (light) level by the dosage of administered hypnotics and analgesics

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Anesthesia is administered as usual
Study: NCT04612413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allocetra-OTS
Description: Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allocetra-OTS
Description: Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allocetra-OTS
Description: Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution containing all excipients except for the Allocetra-OTS cells
Study: NCT01992315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adipose-derived ECM
Description: Each syringe of adipose-derived ECM will hold 2mL and will be for single use only. Up to 3 syringes (6mL total) may be used for each patient. Injections will be made under local anesthesia and sterile conditions using a 23-gauge needle. All injections will be performed in an outpatient clinic setting at study site by the principal investigator who will determine the method, depth, and volume of each implant. Decellularized adipose tissue-derived matrix will be infiltrated into the defect and the underlying musculature as well as the subcutaneous tissue surrounding the defect, with the goal of creating a smooth transition from surrounding structures to the filled defect. This will be performed using a series of multiple punctures or a single puncture with a fanning or threading technique. After the injection is completed, the treatment area will be massaged to conform to the contour of the surrounding tissue and ice will be applied as needed for swelling.
Study: NCT04650906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindhelper - a national youth mental health promotion website
Description: Mindhelper is a fully digital youth mental health service reaching out to a large number of young people when and where they need it, with full anonymity. Mindhelper was developed in 2014-2017 by Centre for Telepsychiatry in the Region of Southern Denmark in a partnership with four Danish municipalities. The development of the site was funded by the Danish foundation TrygFonden. The original idea behind the site was inspired by the Australian youth mental health promotion service ReachOut.com. The Mindhelper service was launched in September 2016. From January 2019 Mindhelper received permanent funding through a joint agreement between the five Danish Regions. Mindhelper is Denmark's most comprehensive youth mental health promotion website where young people can seek mental health information, advice, and self-help tools to improve their mental health and well-being. Since it was launched, the site has been very successful in attracting large numbers of visitors.
Study: NCT02689882

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nicotinamide riboside
Description: Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
Study: NCT04824755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yune Zhao
Description: Yune Zhao did congenital cataract surgeries

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yune Zhao
Description: Yune Zhao did congenital cataract surgeries

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yune Zhao
Description: Yune Zhao did congenital cataract surgeries

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yune Zhao
Description: Yune Zhao did congenital cataract surgeries
Study: NCT05290480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: expiratory muscle training
Description: participants performed expiratory muscle training according to their maximum expiratory pressure that measured earlier in addition to conventional chest physiotherapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insentive spirometry
Description: participants performed deep breating exercise with insentive spirometry in additional to convantional chest physiotherapy
Study: NCT02903524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome injection and cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pirarubicin and cyclophosphamide
Study: NCT02939716

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhubarb
Description: 300gm rhubarb

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: 2 slices bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lettuce
Description: 300g lettuce
Study: NCT02970019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: Once a day administration after fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once a day administration after fast
Study: NCT02111720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maybe, Maybe Not
Description: The goals of session one are to introduce participants to the intervention, to assess current decision context, to assist in the clarification of participant values, and to encourage the participant to set specific goals for disclosure decision-making. The goals for session two are to explore the participants' motivations to disclose or not to disclose and the potential costs and rewards of both disclosing and not disclosing. The goals for session three are to guide participants through disclosure decision making, and to support comfort/acceptance with decisions made. The goal of session four is to support the decision-making process. The booster session is used to reinforce the effects of the intervention through continued discussion of disclosure decisions in the preceding months, strategies used in disclosing, and rewards and costs of decision-making.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Risk Counseling and Services
Description: CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients.
Study: NCT02651519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine hydrochloride
Description: stellate-ganglion block with 0.25% ropivacaine hydrochloride

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: saline
Description: stellate-ganglion block with saline
Study: NCT01179737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib capsules for oral administration at 50 mg, 150 mg twice a day and 300 mg (2 capsules of 150 mg) twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to nilotinib
Description: Placebo to nilotinib capsules for oral administration to match 50 mg, 150 mg and 300 mg capsules twice a day
Study: NCT03235115

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Methafilcon A IV
Description: Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Methafilcon A IV
Description: Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ocufilcon B
Description: Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ocufilcon B
Description: Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omafilcon A
Description: Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omafilcon A
Description: Contact Lens
Study: NCT00299559

Intervention type: DRUG
Group type: OTHER
Intervention: smart textiles containing menthol, camphor, cineol
Description: application to skin
Study: NCT03667417

Intervention type: OTHER
Intervention: Questionnaires
Description: standardized data collection and 10-year prospective follow-up
Study: NCT00947024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.
Study: NCT00436098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motorpedagogic exercise
Description: physical training
Study: NCT03600012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling Functional Electrical Stimulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Study: NCT00329641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally